Comparison of 68Ga-Somatostatin Analogues, 18F-DOPA and 18F-FDG PET/CT in Patients with Recurrent Medullary Thyroid Carcinoma

#351

Introduction: Early detection of recurrences is a crucial step in the management of patients (pts) with medullary thyroid carcinoma (MTC). Currently, there is growing interest for PET tracers in MTC such as: 18F-FDG (reflecting glucose metabolism), 18F-DOPA (reflecting amine decarboxylation), 68Ga-somatostatin analogues (reflecting somatostatin receptors expression)

Aim(s): to compare PET/CT with 68Ga-somatostatin analogues, 18F-DOPA and 18F-FDG in a series of pts with suspected recurrent MTC on the basis of increased calcitonin levels during follow-up, but with conventional imaging inconclusive for loco-regional and/or metastatic spread

Materials and methods: Eighteen pts (6M/12F; mean age 53.5 years) who had performed PET/CT with 68Ga-somatostatin analogues, 18F-DOPA and 18F-FDG within 3 months were selected. Comparison of the results was done on a per-patient and on a per-lesion basis. Verification of PET/CT findings was achieved by histopathology (13 cases) or imaging follow-up (5 cases)

Conference:

Presenting Author:

Authors: Treglia G, Castaldi P, Villani M, Filice A, Ambrosini V,

Keywords: PET/CT; medullary thyroid carcinoma; recurrence diagnosis.,

To read the full abstract, please log into your ENETS Member account.